drugset / Trial / NCT00423449

Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

NCT00423449

Phase 1 Completed 61 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.

Timeline

Start
2007-03
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2
Subject Gemcitabine Small molecule 1250 mg/m2
Subject Vorinostat Small molecule 300 mg
Subject Vorinostat Small molecule 500 mg